Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DTYMK | P23919 | 2/20 | 0.66 |
| ▸ | KAT2B | Q92831 | 9/20 | 0.51 |
| ▸ | TGM2 | P21980 | 3/20 | 0.50 |
| ▸ | EP300 | Q09472 | 3/20 | 0.49 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.49 |
| ▸ | KAT2A | Q92830 | 3/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.48 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.48 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18897799 | 0.83 | DTYMK (0.77) | DTYMKKAT2BTGM2EP300CREBBP | |
| SCHEMBL17782895 | 0.80 | DTYMK (1.00) | DTYMKKAT2BTGM2EP300CREBBP | |
| SCHEMBL9278726 | 0.80 | DTYMK (0.63) | DTYMKKAT2BKAT2A | |
| SCHEMBL18897747 | 0.79 | DTYMK (0.70) | DTYMKKAT2BTGM2EP300CREBBP | |
| SCHEMBL17790400 | 0.78 | DTYMK (0.71) | DTYMKKAT2BTGM2EP300CREBBP | |
| SCHEMBL17782929 | 0.77 | DTYMK (0.58) | DTYMKKAT2BTGM2EP300CREBBP | |
| SCHEMBL11034977 | 0.75 | GAA (0.46) | DTYMK | |
| SCHEMBL17782869 | 0.74 | DTYMK (0.63) | DTYMKKAT2BTGM2 | |
| SCHEMBL21996011 | 0.74 | KAT2B (0.66) | DTYMKKAT2BEP300CREBBPKAT2A | |
| SCHEMBL22056077 | 0.74 | KAT2B (0.69) | DTYMKKAT2BEP300CREBBPKAT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9662328-B2 | Targeting human thymidylate kinase induces DNA repair toxicity in malignant tumor cells | NATIONAL TAIWAN UNIVERSITY (TW) | 2017-05-30 | — | — | US | disclosed |
| US-9662328-B2 | Targeting human thymidylate kinase induces DNA repair toxicity in malignant tumor cells | NATIONAL TAIWAN UNIVERSITY (TW) | 2017-05-30 | — | — | US | disclosed |
| US-9662328-B2 | Targeting human thymidylate kinase induces DNA repair toxicity in malignant tumor cells | NATIONAL TAIWAN UNIVERSITY (TW) | 2017-05-30 | — | — | US | disclosed |
| US-20160151362-A1 | TARGETING HUMAN THYMIDYLATE KINASE INDUCES DNA REPAIR TOXICITY IN MALIGNANT TUMOR CELLS | NATIONAL TAIWAN UNIVERSITY (TW) | 2016-06-02 | — | — | US | disclosed |
| US-20160151362-A1 | TARGETING HUMAN THYMIDYLATE KINASE INDUCES DNA REPAIR TOXICITY IN MALIGNANT TUMOR CELLS | NATIONAL TAIWAN UNIVERSITY (TW) | 2016-06-02 | — | — | US | disclosed |
| US-20160151362-A1 | TARGETING HUMAN THYMIDYLATE KINASE INDUCES DNA REPAIR TOXICITY IN MALIGNANT TUMOR CELLS | NATIONAL TAIWAN UNIVERSITY (TW) | 2016-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160151362-A1 | TARGETING HUMAN THYMIDYLATE KINASE INDUCES DNA REPAIR TOXICITY IN MALIGNANT TUMOR CELLS | DTYMK, TYMP, TK1 | DTYMK 1/4885KAT2B 4241/4885TGM2 822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.